Amarin Corp Plc (AMRN)

[ziploc_1]

The authorities in the FDA are looking to get noticed and stand out amongst the masses. One way to get noticed is to be regarded as a "protector of the public interest". The Amarin Adcom presented such an opportunity. An important factor in their decision to rig the Adcom was an assumption that, if Anchor were approved, Vascepa would have a market TEN times the present one, or approximately 40 MILLION people. By arranging for the rejection of Anchor, if R-IT turns out to be a failure, they would most certainly be noticed...(and probably promoted) If R-IT turns out to be successful, their ploy would be quickly forgotten. For them, it was certainly worth the risk.